Multiple Myeloma: Past, Present and Future

Multiple Myeloma: Past, Present and Future

Multiple Myeloma: Past, Present and Future

Presented By: Kareem Azab, PhD

Speaker Biography: Prof. Azab earned a Pharmacy degree (2000), MSc in Medicinal Chemistry (2003) and a Ph.D. in Pharmaceutical Sciences (2007) from The Hebrew University of Jerusalem, and completed post-doctoral training focusing on biology of hematologic malignancies at Harvard Medical School/Dana-Farber Cancer Institute in 2012. Prof. Azab has co-authored over 80 peer-reviewed papers and 10 patents, and mentored over 40 Post-doctoral, PhD, MSc and Undergraduate Students.

Webinar: Multiple Myeloma: Past, Present and Future

Webinar Abstract: Multiple myeloma (MM) is a cancer of plasma cells that is associated with low blood counts, bone and calcium disorders and infections. Despite advances in treatment in the past decade, the number of deaths associated with MM has not decreased. The pros and cons of bone marrow analysis are discussed: Cytogenetics (Next Gen. Sequencing), flow cytometry and FISH. Three markers and their interactions are used to identify MM cells by flow cytometry: CD138, the gold standard for detection, CD38 and CD45. CD138 is not a reliable marker because hypoxia leads to decreased expression and missed myeloma cells. The findings for a new model that can detect a new subset of myeloma with significant clonality using CD38 as a more specific marker for cell types other than MM cells are discussed.

CC Language: English

Leave a Reply

Your email address will not be published.